Harrow Health/$HROW
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Harrow Health
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
Ticker
$HROW
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
382
ISIN
US4158581094
Website
Harrow Health Metrics
BasicAdvanced
$1.1B
-
-$0.61
0.41
-
Price and volume
Market cap
$1.1B
Beta
0.41
52-week high
$56.01
52-week low
$20.36
Average daily volume
415K
Financial strength
Current ratio
0.907
Quick ratio
0.357
Long term debt to equity
215.848
Total debt to equity
215.848
Interest coverage (TTM)
0.20%
Profitability
EBITDA (TTM)
19.511
Gross margin (TTM)
74.53%
Net profit margin (TTM)
-10.19%
Operating margin (TTM)
2.24%
Effective tax rate (TTM)
-0.75%
Revenue per employee (TTM)
$560,000
Management effectiveness
Return on assets (TTM)
0.90%
Return on equity (TTM)
-37.31%
Valuation
Price to revenue (TTM)
5.185
Price to book
19.63
Price to tangible book (TTM)
-8.72
Price to free cash flow (TTM)
-29.997
Free cash flow yield (TTM)
-3.33%
Free cash flow per share (TTM)
-102.94%
Growth
Revenue change (TTM)
53.49%
Earnings per share change (TTM)
-34.30%
3-year revenue growth (CAGR)
39.06%
10-year revenue growth (CAGR)
52.06%
3-year earnings per share growth (CAGR)
-8.16%
10-year earnings per share growth (CAGR)
-6.44%
What the Analysts think about Harrow Health
Analyst ratings (Buy, Hold, Sell) for Harrow Health stock.
Bulls say / Bears say
Harrow Health's revenue grew by 48.15% year-over-year, reaching $168.04 million, indicating strong sales momentum. (forbes.com)
The company has invested $3.2 million in advanced drug delivery technologies, developing four proprietary platforms targeting ophthalmologic and dermatologic treatments, which could enhance its product portfolio. (dcfmodeling.com)
Harrow Health allocated $2.7 million towards digital health infrastructure, integrating three telemedicine platforms to support remote prescription management and patient consultations, potentially expanding its market reach. (dcfmodeling.com)
Harrow Health reported a net loss of $6.64 million for Q1 2023, compared to a net loss of $2.44 million in the same period the previous year, indicating worsening profitability. (biospace.com)
The company's debt-to-equity ratio stands at 316.8%, reflecting a high level of financial leverage that could pose risks if not managed effectively. (simplywall.st)
Harrow Health's interest coverage ratio is 0.4, suggesting potential difficulties in covering interest expenses from operating earnings. (simplywall.st)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
Harrow Health Financial Performance
Revenues and expenses
Harrow Health Earnings Performance
Company profitability
Harrow Health News
AllArticlesVideos
Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications
Business Wire·2 weeks ago
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
Business Wire·3 weeks ago
Harrow to Present at Two Investor Conferences in May
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Harrow Health stock?
Harrow Health (HROW) has a market cap of $1.1B as of June 30, 2025.
What is the P/E ratio for Harrow Health stock?
The price to earnings (P/E) ratio for Harrow Health (HROW) stock is 0 as of June 30, 2025.
Does Harrow Health stock pay dividends?
No, Harrow Health (HROW) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Harrow Health dividend payment date?
Harrow Health (HROW) stock does not pay dividends to its shareholders.
What is the beta indicator for Harrow Health?
Harrow Health (HROW) has a beta rating of 0.41. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.